🔍

Sandu Pharmaceuticals Ltd (524703)

📊 BSE: 524703 🏢 Pharmaceuticals 📢 Latest filing: 30 Sep 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Sandu Pharmaceuticals' revenue was ₹16.4 Cr (-1.9% year on year, -2.7% on the previous quarter), and net profit ₹0.2 Cr (+3.7% year on year); the operating margin was 3.3%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹16.4	-1.9%	-2.7%
Operating profit	₹0.5	+1.3%	-5.8%
Net profit	₹0.2	+3.7%	+470.5%
EPS (₹)	0.37	+60.9%	+825.0%
Operating margin	3.3%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Sandu Pharma Urges Physical Shareholders to Update PAN and KYC Details per SEBI Norms

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Sep 2026, 12:18 PM

Sandu Pharmaceuticals Limited has issued intimations to physical shareholders to submit their PAN, KYC details, and bank credentials to its Registrar and Transfer Agent (MUFG Intime India Pvt Ltd) as mandated by SEBI. In line with regulatory rules, failure to update bank details means any declared dividend or interest will only be processed electronically upon submission of complete records. The notice also highlights a special window available until February 04, 2027, for the re-lodgement of transfer deeds rejected prior to April 01, 2019.

Reminder letters dispatched to physical share holders on September 29, 2026
Special window for re-lodgement of transfer deeds open from February 05, 2026 till February 04, 2027
SEBI Master Circular reference dated June 23, 2025 and circular dated February 06, 2026 mandated the compliance
Addresses re-lodgements rejected prior to the deadline of April 01, 2019

💡 Physical share holders should submit Forms ISR-1, ISR-2, and nominee details to RTA MUFG Intime India to prevent dividend delays. Regular investors should track upcoming Q2 FY27 earnings for operational performance.

Sandu Pharmaceuticals Issues AGM Notice & Annual Report Weblink To Unregistered Shareholders

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 19 Aug 2026, 05:41 PM

Sandu Pharmaceuticals has dispatched physical letters providing the weblink to its Annual Report to shareholders whose email addresses are not registered with the company or RTA. The company's 41st Annual General Meeting is scheduled to be held virtually on September 11, 2026, at 4:30 PM. The filing is a routine administrative compliance step under Regulation 36(1)(b) of SEBI LODR Regulations with no impact on operations or financials.

41st Annual General Meeting scheduled for September 11, 2026, at 4:30 PM via video conference
Letters sent to unregistered shareholders based on the cut-off date of August 7, 2026
Compliance intimation under Regulation 36(1)(b) of SEBI LODR Regulations, 2015

💡 Shareholders holding physical shares or with unregistered emails should update their KYC and email details with the RTA to ensure receipt of future corporate communications.

Sandu Pharma Releases 41st Annual Report; FY26 Revenue at ₹69.93 Cr, AGM Set for Sept 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Aug 2026, 05:38 PM

Sandu Pharmaceuticals Limited has released its 41st Annual Report along with the notice for its 41st Annual General Meeting scheduled for September 11, 2026. For FY26, the company reported revenue from operations of ₹6,993.45 lakhs (₹69.93 Cr), up from ₹6,719.24 lakhs in FY25. Net profit increased by 23.187% year-on-year, driven by cost management and operational efficiencies despite higher business promotion expenses of ₹924.59 lakhs.

Annual General Meeting (AGM) scheduled for Friday, 11th September 2026 via VC/OAVM
Revenue from operations reached ₹6,993.45 lakhs in FY26 versus ₹6,719.24 lakhs in FY25
Net profit recorded an increase of 23.187% year-on-year
Business promotion expenses rose to ₹924.59 lakhs from ₹699.21 lakhs in the previous year

💡 Track voting resolutions and commentary from management during the AGM on September 11, 2026, alongside Q2 FY27 quarterly financial results.

Sandu Pharma 41st AGM on Sept 11, 2026; Proposes ₹1.00/Share Dividend & Related-Party Limits

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 19 Aug 2026, 05:33 PM

Sandu Pharmaceuticals has issued the notice for its 41st Annual General Meeting scheduled for September 11, 2026. The agenda includes shareholder approval for a dividend of ₹1.00 per share (10% on face value of ₹10) for FY26. Additionally, the company seeks approval for material related-party transactions with Sandu Brothers Private Limited up to ₹100 crore, alongside the appointment of M/s. Dave & Dave as statutory auditors for a 5-year tenure.

41st Annual General Meeting scheduled for Friday, September 11, 2026 at 4:30 PM via VC/OAVM
Proposed dividend declaration of ₹1.00 per share (10% on ₹10 face value) for FY26
Approval sought for material related-party transactions with Sandu Brothers Private Limited up to ₹100 crore
Appointment of M/s Dave & Dave, Chartered Accountants, as statutory auditors for a 5-year term ending at the 46th AGM in 2031
Ratification of Cost Auditor remuneration of ₹1,30,000 per annum for FY 2026-27

💡 Track shareholder voting results and scrutinize the rationale and terms of the ₹100 crore related-party transaction limit relative to company revenue (₹67 crore TTM).

Sandu Pharma Q1 Net Profit Flat at Rs 0.23 Cr; Material Related Party Transactions Proposed

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 06:41 PM

Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at Rs 16.39 Cr compared to Rs 16.70 Cr in the previous year. Net profit remained stable at Rs 0.23 Cr, while EPS improved slightly to Rs 0.37 from Rs 0.23 YoY. The board has recommended the continuation of material related party transactions with Sandu Brothers Private Limited, pending shareholder approval at the AGM on September 11, 2026. A record date of September 4, 2026, has been set for the FY26 dividend eligibility.

Revenue from operations for Q1 FY27 stood at Rs 16.39 Cr, a marginal decline of 1.8% compared to Rs 16.70 Cr in Q1 FY26.
Net profit for the quarter was Rs 0.23 Cr, showing minimal change from the Rs 0.22 Cr reported in the same period last year.
Record date for the FY26 dividend is fixed for September 4, 2026, with the AGM scheduled for September 11, 2026.
Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term starting from the conclusion of the upcoming AGM.
Board recommended shareholder approval for material related party transactions with M/s. Sandu Brothers Private Limited.

💡 Monitor the shareholder voting outcome regarding the material related party transactions at the AGM and track if the company can improve its low operating margins (4.1%) in upcoming quarters.

Sandu Pharmaceuticals reports zero deviation in utilization of Rs 5.34 Cr raised funds

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 11 Aug 2026, 06:38 PM

Sandu Pharmaceuticals has filed its quarterly statement of deviation for the period ended June 30, 2026, confirming that funds raised through preferential issues between 2021 and 2022 are being used as intended. The company raised a total of approximately Rs 5.34 Cr across three tranches to fund plant revamping, marketing infrastructure, and working capital. While the first two tranches are fully utilized, the third tranche of Rs 1.32 Cr remains partially unutilized and is currently held in a Fixed Deposit with Bank of Baroda. This is a routine regulatory disclosure with no reported deviations or changes in objects.

Total funds raised across three preferential tranches between March 2021 and July 2022 amount to Rs 5.34 Cr.
Tranche 1 raised Rs 2.64 Cr on March 31, 2021, for revamping capital and marketing infrastructure.
Tranche 2 raised Rs 1.38 Cr on February 28, 2022, via warrant conversion at Rs 20.69 per share.
Tranche 3 raised Rs 1.32 Cr on July 14, 2022, with Rs 46.56 lakh utilized as of the reporting date.
Unutilized proceeds are currently maintained in a Fixed Deposit with Bank of Baroda.

💡 Investors should monitor the completion of the 'revamping of capital' and 'plant and machinery' purchases, as these are intended to enhance the company's business scale.

Sandu Pharmaceuticals Q1 Revenue at Rs 16.39 Cr; Appoints New Statutory Auditor

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 06:15 PM

Sandu Pharmaceuticals reported a flat Q1 FY27 with revenue of Rs 16.39 Cr, a marginal 1.8% decline from Rs 16.70 Cr in the same quarter last year. Net profit remained stable at Rs 0.23 Cr, matching the previous year's performance. The board has recommended the appointment of M/s Dave & Dave as statutory auditors for a five-year term (FY27-FY31). Additionally, the company set September 4, 2026, as the record date for the FY26 dividend and is seeking shareholder approval for material related-party transactions with Sandu Brothers Private Limited.

Q1 FY27 Revenue reported at Rs 16.39 Cr, down 1.8% from Rs 16.70 Cr YoY
Net Profit for the quarter ended June 2026 stood at Rs 0.23 Cr, identical to Q1 FY26
Appointment of M/s Dave & Dave as Statutory Auditors for a 5-year term starting FY27
Record date for FY26 dividend eligibility set for September 4, 2026
Total expenses for the quarter were Rs 16.05 Cr, slightly lower than Rs 16.38 Cr in the year-ago period

💡 Monitor the approval of material related-party transactions at the AGM on September 11, 2026, and observe if the company can break out of its stagnant revenue range in upcoming quarters.

Sandu Pharmaceuticals Q1 Net Profit Flat at ‡0.23 Cr; Sets Sept 4 as Dividend Record Date

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 06:07 PM

Sandu Pharmaceuticals reported a stagnant performance for Q1 FY27, with net profit remaining flat at ‡0.23 crore compared to the previous year. Revenue from operations saw a marginal decline of 1.8% year-on-year to ‡16.39 crore. The company has scheduled its 41st Annual General Meeting for September 11, 2026, and fixed September 4, 2026, as the record date for the proposed dividend. Additionally, the board has recommended the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term.

Revenue from operations stood at ‡16.39 crore for Q1 FY27, down from ‡16.70 crore in Q1 FY26.
Net profit for the quarter was ‡0.23 crore (reported as ‡22.83 lakhs), nearly identical to ‡22.33 lakhs in the year-ago period.
Record date for determining dividend eligibility is fixed as Friday, September 4, 2026.
Total expenses for the quarter were ‡16.05 crore, slightly lower than ‡16.38 crore in the corresponding quarter last year.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a 5-year term until 2031.

💡 Investors should monitor the upcoming AGM on September 11 for details on the 'Material Related Party Transactions' with Sandu Brothers Pvt Ltd and any management commentary on improving the low operating margins (currently ~4%).

Sandu Pharma Q1 Revenue at ₹16.39 Cr; Dividend Record Date Set for Sept 4, 2026

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 11 Aug 2026, 06:05 PM

Sandu Pharmaceuticals reported a flat Q1 FY27 with revenue of ₹16.39 cr, compared to ₹16.70 cr in the same quarter last year. Net profit for the quarter stood at ₹0.23 cr, showing marginal growth in EPS to 0.37 from 0.23 YoY. The board has fixed September 4, 2026, as the record date for the FY26 dividend. Additionally, a new statutory auditor, M/s. Dave & Dave, has been recommended for a five-year term starting from the upcoming AGM on September 11, 2026.

Revenue from operations for Q1 FY27 stood at ₹16.39 cr, representing ~24.5% of TTM revenue.
Net profit for the quarter was ₹0.23 cr, compared to ₹0.23 cr in the corresponding quarter of the previous year.
Record date for determining dividend eligibility is fixed as September 4, 2026.
Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term until 2031.
The 41st Annual General Meeting (AGM) is scheduled for September 11, 2026.

💡 Investors should monitor the details of the 'Material Related Party Transactions' with Sandu Brothers Private Limited which are up for shareholder approval at the AGM.

Sandu Pharma Q1 Net Profit at ₹0.23 Cr; Sets Sept 4 as Record Date for Dividend

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 06:03 PM

Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at ₹16.39 Cr compared to ₹16.70 Cr in the previous year. Net profit remained stable at ₹0.23 Cr, while EPS improved slightly to ₹0.37 from ₹0.23. The board has fixed September 4, 2026, as the record date for the proposed FY26 dividend. Additionally, the company has proposed the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term.

Q1 FY27 revenue from operations stood at ₹16.39 Cr, contributing approximately 24.5% to TTM revenue.
Net profit for the quarter was ₹0.23 Cr, showing minimal change from ₹0.22 Cr in Q1 FY26.
Record date for determining dividend eligibility for FY26 is fixed as September 4, 2026.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.
Approval sought for material related-party transactions with M/s. Sandu Brothers Private Limited at the upcoming AGM.

💡 Investors should note the September 4 record date for dividend eligibility and monitor the AGM outcome regarding the approval of material related-party transactions.

Sandu Pharma Q1 Revenue at ₹16.39 Cr; Sets Sept 4 as Dividend Record Date

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 11 Aug 2026, 05:59 PM

Sandu Pharmaceuticals reported a flat performance for Q1 FY27, with revenue from operations at ₹16.39 crore compared to ₹16.70 crore in the same quarter last year. Net profit remained stable at ₹0.23 crore, matching the year-ago period. The board has fixed September 4, 2026, as the record date for the proposed FY26 dividend. Additionally, the company has recommended the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term and is seeking approval for material related-party transactions.

Revenue from operations for Q1 FY27 was ₹16.39 crore, representing a marginal 1.8% decline YoY.
Net profit for the quarter stood at ₹0.23 crore, identical to the ₹0.23 crore reported in Q1 FY26.
Record date for determining dividend eligibility for FY26 is fixed as September 4, 2026.
The 41st Annual General Meeting (AGM) is scheduled for September 11, 2026, via video conferencing.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term (2026-2031).

💡 Investors should monitor the upcoming AGM on September 11, 2026, specifically for the approval of material related-party transactions with Sandu Brothers Private Limited and the company's ability to scale its low operating margins.

Rs 16.39 Cr Revenue: Sandu Pharmaceuticals Q1 FY27 Results Flat YoY; New Auditor Appointed

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 11 Aug 2026, 05:46 PM

Sandu Pharmaceuticals reported a marginal revenue decline of 1.8% YoY to Rs 16.39 Cr for the quarter ended June 30, 2026. Net profit remained stagnant at Rs 0.23 Cr, mirroring the performance of the same quarter last year, though it recovered from a low of Rs 0.02 Cr in the preceding March quarter. The company has fixed September 4, 2026, as the record date for its FY26 dividend. A significant governance update includes the proposed appointment of M/s. Dave & Dave as statutory auditors for a five-year term.

Revenue from operations stood at Rs 16.39 Cr, down 1.8% from Rs 16.70 Cr in Q1 FY26.
Net profit for the quarter was Rs 0.23 Cr, representing a thin net margin of 1.4%.
Total expenses were slightly reduced to Rs 16.05 Cr from Rs 16.38 Cr in the year-ago period.
Record date for the FY26 dividend is set for September 4, 2026, with the AGM scheduled for September 11, 2026.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.

💡 Investors should monitor the upcoming AGM for details on 'Material Related Party Transactions' with Sandu Brothers Private Limited and observe if the new auditor appointment leads to changes in financial reporting disclosures.

Sandu Pharmaceuticals Q1 PAT at ₹0.23 Cr; Dividend Record Date Set for Sept 4

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 11 Aug 2026, 05:39 PM

Sandu Pharmaceuticals reported a flat performance for Q1 FY27, with a net profit of ₹0.23 Cr, nearly identical to the ₹0.22 Cr reported in the same quarter last year. Revenue from operations declined marginally by 1.8% YoY to ₹16.39 Cr. The company has fixed September 4, 2026, as the record date for its FY26 dividend. Additionally, the board has proposed the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term and is seeking approval for material related-party transactions.

Revenue from operations for Q1 FY27 stood at ₹16.39 Cr, compared to ₹16.70 Cr in Q1 FY26.
Net profit for the quarter remained stagnant at ₹0.23 Cr (₹22.84 lakhs).
Record date for the FY26 dividend is fixed for September 4, 2026, with the AGM scheduled for September 11, 2026.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.
Total expenses for the quarter were ₹16.05 Cr, accounting for 97.8% of total income.

Sandu Pharmaceuticals Q1 Net Profit at ₹0.23 Cr; Dividend Record Date Set for Sept 4

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 11 Aug 2026, 05:24 PM

Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at ₹16.39 Cr compared to ₹16.70 Cr in the same period last year. Net profit remained stable at ₹0.23 Cr, showing a recovery from the ₹0.02 Cr reported in the preceding quarter (March 2026). The board has fixed September 4, 2026, as the record date for the proposed FY26 dividend. Additionally, the company is seeking shareholder approval for material related party transactions and the appointment of new statutory auditors for a five-year term.

Revenue from operations for Q1 FY27 stood at ₹16.39 Cr, a marginal decline of 1.8% YoY.
Net profit for the quarter was ₹0.23 Cr, nearly identical to the ₹0.22 Cr reported in Q1 FY26.
Record date for determining dividend eligibility is fixed as September 4, 2026.
Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term until 2031.
Total Comprehensive Income for the period was ₹0.38 Cr, supported by fair value changes in investments.

💡 Investors should monitor the upcoming AGM on September 11, 2026, specifically for the approval of material related party transactions with Sandu Brothers Private Limited.

Board Meeting Scheduled for August 11, 2026, to Approve Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 03 Aug 2026, 02:52 PM

Sandu Pharmaceuticals has scheduled a board meeting for August 11, 2026, to consider and approve the standalone unaudited financial results for the quarter ended June 30, 2026. This is a routine regulatory filing for a micro-cap company with a market capitalization of Rs 38 Cr. In the previous year's corresponding quarter (June 2024), the company reported a revenue of Rs 17.05 Cr and a net profit of Rs 0.17 Cr. Investors will be monitoring if the company can improve its thin operating margins, which stood at 4.1% for FY25.

Board meeting to be held on August 11, 2026, at 04:00 p.m. in Mumbai.
Financial results to be reviewed for the quarter ended June 30, 2026.
Trading window has been closed since July 1, 2026, for directors and designated employees.
Company reported TTM revenue of Rs 67 Cr and TTM PAT of Rs 2 Cr.
Promoter holding remained stable at 37.79% as of June 2026.

💡 Monitor the financial results on August 11, 2026, to check for any improvement in operating margins and revenue growth compared to the Rs 17.05 Cr reported in June 2024.

View All 524703 Announcements on Live Market Tracking →